![Sheraz Mian Sheraz Mian](https://staticx.zacks.com/images/mugshots/sheraz_mian/sheraz_mian-4.png)
Top Analyst Reports for Alibaba, Abbott & T-Mobile US
![](https://staticx.zacks.com/images/zt/ztNow_icon2.png)
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Alibaba Group Holding Limited (BABA), Abbott Laboratories (ABT), and T-Mobile US, Inc. (TMUS). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Shares of Alibaba have underperformed the S&P 500 in the past three months (-17.7% vs. +5.8%). The company is susceptible to certain risks due to the strict laws in China, which along with lower mobile monetization, increasing competition and integration risks have been weighing on its revenues.
The Zacks analyst, however, believes that its dominance in the mobile commerce market, continued efforts to develop new products, international growth opportunities and strong financial position are some of the near-term tailwinds. The company’s strengthening cloud business on the back of its expanding customer base also continues to drive its performance.
(You can read the full research report on Alibaba here >>>)
Abbott shares have gained +17.3% in the year to date period against the Zacks Medical Products industry’s gain of +2.8%. The Zacks analyst believes that the company’s branded generics and international diabetes businesses are likely to drive growth in the quarters ahead.
Abbott reported better-than-expected earnings for the third quarter of 2021. Barring Neuromodulation, the company registered organic sales growth across each of its operating segments. Diabetes Care sales, in the quarter, also benefited from the solid worldwide adoption of FreeStyle Libre. A challenging business environment and slow growth in the nutrition business in China are some of the major headwinds though.
(You can read the full research report on Abbott here >>>)
Shares of T-Mobile US have lost -4.2% over the past year against the Zacks National Wireless industry’s loss of -7.4%. The company is, however, expanding its 5G network to bring fast and affordable wireless service across the country. The Zacks analyst believes that such developments would unlock massive synergies for it.
It has expanded its Home Internet service to 51 cities across Florida, Georgia, North Carolina, and South Carolina. T-Mobile’s Extended Range 5G covers 308 million people across 1.7 million square miles. The company, however, operates in a fiercely competitive and an almost saturated U.S. telecom market which has been weighing on its revenues.
(You can read the full research report on T-Mobile US here >>>)
Other noteworthy reports we are featuring today include Anheuser-Busch InBev SA/NV (BUD), Boston Scientific Corporation (BSX) and EOG Resources, Inc. (EOG).
Sheraz Mian
Director of Research
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
Get the latest research report on ABT - FREE
Get the latest research report on BSX - FREE
Get the latest research report on EOG - FREE
Get the latest research report on BUD - FREE
Get the latest research report on TMUS - FREE
Get the latest research report on BABA - FREE